Roche Holding 과거 순이익 실적

과거 기준 점검 4/6

Roche Holding의 수입은 연평균 -6.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 4.6% 감소했습니다. 매출은 연평균 0.9%의 비율로 감소해 왔습니다. Roche Holding의 자기자본이익률은 36.2%이고 순이익률은 19.6%입니다.

핵심 정보

-6.08%

순이익 성장률

-4.66%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률	16.33%
매출 성장률	-0.92%
자기자본이익률	36.20%
순이익률	19.60%
다음 순이익 업데이트	22 Oct 2026

최근 과거 실적 업데이트

분석 기사 • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

Recent updates

내러티브 업데이트 • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

분석 기사 • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

내러티브 업데이트 • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

분석 기사 • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

내러티브 업데이트 • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

내러티브 업데이트 • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

새로운 내러티브 • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.

새로운 내러티브 • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

새로운 내러티브 • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

매출 및 비용 세부 내역

Roche Holding가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

SWX:ROP 매출, 비용 및 순이익 (CHF Millions)
날짜	매출	순이익	일반관리비	연구개발비
30 Jun 26	62,959	12,341	13,618	12,285
31 Mar 26	63,158	12,611	13,693	12,410
31 Dec 25	63,356	12,880	13,767	12,535
30 Sep 25	63,422	11,155	13,786	12,847
30 Jun 25	63,488	9,429	13,804	13,158
31 Mar 25	62,942	8,853	13,739	13,265
31 Dec 24	62,395	8,277	13,674	13,372
30 Sep 24	61,488	9,448	13,510	13,377
30 Jun 24	60,581	10,619	13,346	13,381
31 Mar 24	60,511	11,059	13,416	13,463
31 Dec 23	60,441	11,498	13,486	13,545
30 Sep 23	61,486	11,263	13,690	13,669
30 Jun 23	62,530	11,028	13,894	13,793
31 Mar 23	64,172	11,725	13,793	13,696
31 Dec 22	65,814	12,421	13,691	13,599
30 Sep 22	66,716	13,539	13,262	13,592
30 Jun 22	67,617	14,657	12,833	13,585
31 Mar 22	66,734	14,294	12,405	13,804
31 Dec 21	65,850	13,930	11,977	14,022
30 Sep 21	63,974	13,975	12,037	13,747
30 Jun 21	62,098	14,019	12,097	13,472
31 Mar 21	61,221	14,157	12,026	13,019
31 Dec 20	60,343	14,295	11,954	12,566
30 Sep 20	61,361	13,626	12,289	12,382
30 Jun 20	62,378	12,957	12,624	12,198
31 Mar 20	63,065	13,227	12,904	12,061
31 Dec 19	63,751	13,497	13,183	11,923
30 Sep 19	62,736	12,654	13,275	11,702
30 Jun 19	61,721	11,810	12,933	11,480
31 Mar 19	60,609	11,155	12,800	11,337
31 Dec 18	59,497	10,500	12,667	11,194
30 Sep 18	58,611	10,483	12,641	11,005
30 Jun 18	57,725	10,465	12,615	10,815
31 Mar 18	56,736	9,549	12,322	10,672
31 Dec 17	55,746	8,633	12,029	10,529
30 Sep 17	54,961	9,154	11,148	10,411
30 Jun 17	54,176	9,675	10,266	10,293
31 Mar 17	53,406	9,626	10,305	10,172
31 Dec 16	52,636	9,576	10,343	10,050
30 Sep 16	52,109	9,332	10,655	9,975
30 Jun 16	51,581	9,087	10,966	9,900
31 Mar 16	50,992	8,975	10,953	9,678
31 Dec 15	50,403	8,863	10,940	9,455
30 Sep 15	50,364	8,908	10,978	9,305

양질의 수익: ROP는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: ROP의 현재 순 이익률 (19.6%)은 지난해 (14.9%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: ROP의 수익은 지난 5년 동안 연평균 6.1% 감소했습니다.

성장 가속화: 지난 1년간 ROP 의 수익 증가율(30.9%)은 연간 평균(-6.1%)을 초과합니다.

수익 대 산업: ROP의 지난 1년 수익 증가율(30.9%)은 Pharmaceuticals 업계 평균(30.9%)을 능가하지 못했습니다.

자기자본이익률

높은 ROE: ROP의 자본 수익률(36.2%)은 높음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/08/20 12:58
종가	2026/08/20 00:00
수익	2026/06/30
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Roche Holding AG는 44명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding 과거 순이익 실적

과거 기준 점검 4/6

핵심 정보

최근 과거 실적 업데이트

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First half 2026 earnings released

Roche Holding AG to Report Q1, 2026 Results on Apr 23, 2026

Recent updates

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology

Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion.

Roche Showcases Ophthalmology Portfolio At Arvo 2026

Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus Erythematosus

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Receives CE Mark for New Elecsys NfL Blood Test to Detect Neuroinflammation in Multiple Sclerosis

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Insufficient new directors

Roche Launches the Cobas MPX-E Assay, A New 4-In-1 Donor Screening Test

Roche Launches the Cobas Eplex Respiratory Pathogen Panel 3

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Roche Holding AG to Report Q1, 2026 Results on Apr 23, 2026

Roche Diagnostics Expands Mass Spectrometry Menu With Steroid Assays Receiving CLIA Moderate Complexity Designation

매출 및 비용 세부 내역

순이익 및 매출 추이

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

자기자본이익률

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터 소스

분석 모델 및 스노우플레이크

산업 및 섹터 지표

분석가 소스